tetano
Editor, Senior Moderator
J Clin Lab Anal
. 2020 Aug 28;e23527.
doi: 10.1002/jcla.23527. Online ahead of print.
Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study
Qian Liu[SUP] 1 [/SUP], Yaping Dai[SUP] 2 [/SUP], Meimei Feng[SUP] 3 [/SUP], Xu Wang[SUP] 2 [/SUP], Wei Liang[SUP] 1 [/SUP], Fumeng Yang[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Serum amyloid A (SAA), interleukin-6 (IL-6) and neutrophil-to-lymphocyte ratio (NLR) play critical roles in inflammation and are used in clinical laboratories as indicators of inflammation-related diseases. We aimed to provide potential laboratory basis for auxiliary distinguishing coronavirus disease (COVID-19) by monitoring above indicators.
Methods: A total of 84 patients with confirmed COVID-19 were enrolled in the study. Baseline characteristics and laboratory results were collected and analyzed. Receiver operating characteristic (ROC) curve analysis was used to combined detection of SAA and IL-6 in patients with COVID-19, and independent risk factors for severity of COVID-19 were assessed by using binary logistic regression.
Results: The main clinical symptoms of patients with COVID-19 were fever (98.8%), fatigue (61.9%), and dry cough (58.3%). SAA, IL-6, and NLR were significantly higher in patients with COVID-19 (all P < .001), and compared with nonsevere patients, three indicators of severe patients were significantly elevated. Besides, combined detection of SAA and IL-6 better separates healthy people from patients with COVID-19 than detection of SAA or IL-6 alone. In addition, elevated SAA, IL-6, and NLR can be used as independent variables for predicting the severity of patients with COVID-19.
Conclusion: Serum amyloid A and IL-6 could be used as addition parameters to helping the distinguish of patients with COVID-19 from healthy people, and can provide potential basis for separating patients with nonsevere and severe clinical signs.
Keywords: coronavirus disease; interleukin-6; serum amyloid A; severe acute respiratory syndrome coronavirus 2.
. 2020 Aug 28;e23527.
doi: 10.1002/jcla.23527. Online ahead of print.
Associations between serum amyloid A, interleukin-6, and COVID-19: A cross-sectional study
Qian Liu[SUP] 1 [/SUP], Yaping Dai[SUP] 2 [/SUP], Meimei Feng[SUP] 3 [/SUP], Xu Wang[SUP] 2 [/SUP], Wei Liang[SUP] 1 [/SUP], Fumeng Yang[SUP] 1 [/SUP]
Affiliations
- PMID: 32860278
- DOI: 10.1002/jcla.23527
Abstract
Background: Serum amyloid A (SAA), interleukin-6 (IL-6) and neutrophil-to-lymphocyte ratio (NLR) play critical roles in inflammation and are used in clinical laboratories as indicators of inflammation-related diseases. We aimed to provide potential laboratory basis for auxiliary distinguishing coronavirus disease (COVID-19) by monitoring above indicators.
Methods: A total of 84 patients with confirmed COVID-19 were enrolled in the study. Baseline characteristics and laboratory results were collected and analyzed. Receiver operating characteristic (ROC) curve analysis was used to combined detection of SAA and IL-6 in patients with COVID-19, and independent risk factors for severity of COVID-19 were assessed by using binary logistic regression.
Results: The main clinical symptoms of patients with COVID-19 were fever (98.8%), fatigue (61.9%), and dry cough (58.3%). SAA, IL-6, and NLR were significantly higher in patients with COVID-19 (all P < .001), and compared with nonsevere patients, three indicators of severe patients were significantly elevated. Besides, combined detection of SAA and IL-6 better separates healthy people from patients with COVID-19 than detection of SAA or IL-6 alone. In addition, elevated SAA, IL-6, and NLR can be used as independent variables for predicting the severity of patients with COVID-19.
Conclusion: Serum amyloid A and IL-6 could be used as addition parameters to helping the distinguish of patients with COVID-19 from healthy people, and can provide potential basis for separating patients with nonsevere and severe clinical signs.
Keywords: coronavirus disease; interleukin-6; serum amyloid A; severe acute respiratory syndrome coronavirus 2.